FDA Investigator

Kemejumaka N Opara

Latest inspection on record: West Columbia, United States, April 2022 · records back to 2020

Human Drugs

FDA inspection record · Last updated July 12, 2026

Overview

  • 8 inspections across 8 sites are on record.
  • 28 Form 483 observations are attributed to this investigator.
  • Most recent recorded activity is 2022-04-20.

At a glance

Inspections

8

Sites

8

Observations

28

Career since

Feb 2020

Recent inspections

Most recent inspections in the published record.

SiteDateCategoryForm 483
Nephron Sterile Compounding Center, LLC20 Apr 2022Human DrugsView 483 →
Nephron SC, LLC20 Apr 2022Human DrugsView 483 →
The Procter & Gamble Manufacturing Company18 Feb 2022Human DrugsView 483 →
PharmAgra Labs Inc17 Nov 2021Human Drugs
Coty US LLC27 Oct 2021Human DrugsView 483 →

Sites inspected

Nephron Sterile Compounding Center, LLCWest Columbia, United States1 insp.
Nephron SC, LLCWest Columbia, United States1 insp.
The Procter & Gamble Manufacturing CompanyBrowns Summit, United States1 insp.
PharmAgra Labs IncBrevard, United States1 insp.
Coty US LLCSanford, United States1 insp.

Co-investigators

Investigators who share inspections with this person.

Full investigator report

Get the verbatim findings behind Kemejumaka N Opara's 28 observations

Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.

  • New inspections and Form 483s, mapped to the CFR citation
  • Warning letter outcomes, and the citation patterns they repeat
  • Their co-investigators, so no surprises about who shows up on site